Skip to main content
Premium Trial:

Request an Annual Quote

Merger Hyseq, Variagenics Unite With Acrobatic Accounting


The Hyseq/Variagenics merger may have been a surprise to the rest of the industry, but the way Hyseq CEO Ted Love tells it, the match was virtually destiny. “We brought them our upside, they manage our downside,” he quips.

But in this case, destiny was far from straightforward. The merger, in which Hyseq essentially bought Variagenics by issuing enough stock to cover the cash Variagenics had on hand — about $60 million — will result in a new company owned 64 percent by Variagenics and 36 percent by Hyseq.

The path to the new company, which has yet to undergo its naming and logo-ing process, began a year ago. “Variagenics started to look at possible M&A opportunities as long as 14 to 18 months ago,” Love said in late November, at the time of the merger announcement. Hyseq began looking at the beginning of 2002, and Love happened to have a “chance interaction with one of their board members” at a February meeting in New York. “They talked to other companies, and so did we,” Love says. Finally, both companies settled on this merger.

Love says Variagenics’ emphasis on products, primarily through its molecular diagnostics unit, was appealing to Hyseq, which is trying mightily to get its first biotherapeutic through clinical trials. “They fit the sweet spot for what we thought would make sense for us,” he says. Hyseq’s main problem was its lack of cash, and Variagenics’ $60 million coffers looked awfully good, Love acknowledges. Layoffs are inevitable, and approximately 90 staffers are expected to be let go. Relocations for the rest, though, are unlikely — Love anticipates that each unit will remain where it was, one in Sunnyvale, Calif., and the other in Cambridge, Mass.

The future of the merger is as non-linear as its beginnings. To avoid a taxable transaction, Hyseq will spin out a shell company, which will team up with Variagenics, and then Hyseq will spin the shell back in. Hyseq’s stock was chosen as the survivor, but its ticker symbol will change as soon as the merger is approved (target: February) and the new company is named.

Love hopes Hyseq’s first drug will be through trials and submitted to the FDA by 2005. Meantime, Variagenics has a diagnostic in the works that could get to market as early as 2004. Throughout, Love views as a model the biotech giant Amgen, with revenues “north of $60 billion to $70 billion” based almost entirely on just two products, he says.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.